150 related articles for article (PubMed ID: 18846510)
1. Chemokine receptor CCR2 undergoes transportin1-dependent nuclear translocation.
Favre N; Camps M; Arod C; Chabert C; Rommel C; Pasquali C
Proteomics; 2008 Nov; 8(21):4560-76. PubMed ID: 18846510
[TBL] [Abstract][Full Text] [Related]
2. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.
O'Boyle G; Brain JG; Kirby JA; Ali S
Mol Immunol; 2007 Mar; 44(8):1944-53. PubMed ID: 17081610
[TBL] [Abstract][Full Text] [Related]
3. Cloning and functional characterization of the rabbit C-C chemokine receptor 2.
Lu D; Yuan XJ; Evans RJ; Pappas AT; Wang H; Su EW; Hamdouchi C; Venkataraman C
BMC Immunol; 2005 Jul; 6():15. PubMed ID: 16001983
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in CCR2 antagonists.
Xia M; Sui Z
Expert Opin Ther Pat; 2009 Mar; 19(3):295-303. PubMed ID: 19441905
[TBL] [Abstract][Full Text] [Related]
5. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis.
Rafei M; Berchiche YA; Birman E; Boivin MN; Young YK; Wu JH; Heveker N; Galipeau J
J Immunol; 2009 Aug; 183(3):1759-66. PubMed ID: 19592643
[TBL] [Abstract][Full Text] [Related]
6. n-Nonanoyl-CCL14 (NNY-CCL14), a novel inhibitor of allergic airway inflammation is a partial agonist of human CCR2.
Gupta S; Erdmann G; Schulz-Maronde S; Escher SE; Richter R; Forssmann WG; Elsner J; Forssmann U
Allergy; 2008 Oct; 63(10):1317-23. PubMed ID: 18782110
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2.
Buntinx M; Hermans B; Goossens J; Moechars D; Gilissen RA; Doyon J; Boeckx S; Coesemans E; Van Lommen G; Van Wauwe JP
J Pharmacol Exp Ther; 2008 Oct; 327(1):1-9. PubMed ID: 18599682
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2.
Shin N; Baribaud F; Wang K; Yang G; Wynn R; Covington MB; Feldman P; Gallagher KB; Leffet LM; Lo YY; Wang A; Xue CB; Newton RC; Scherle PA
Biochem Biophys Res Commun; 2009 Sep; 387(2):251-5. PubMed ID: 19576173
[TBL] [Abstract][Full Text] [Related]
9. Chemokine-binding specificity of soluble chemokine-receptor analogues: identification of interacting elements by chimera complementation.
Datta-Mannan A; Stone MJ
Biochemistry; 2004 Nov; 43(46):14602-11. PubMed ID: 15544331
[TBL] [Abstract][Full Text] [Related]
10. Synergy-inducing chemokines enhance CCR2 ligand activities on monocytes.
Kuscher K; Danelon G; Paoletti S; Stefano L; Schiraldi M; Petkovic V; Locati M; Gerber BO; Uguccioni M
Eur J Immunol; 2009 Apr; 39(4):1118-28. PubMed ID: 19291700
[TBL] [Abstract][Full Text] [Related]
11. FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration.
Toda E; Terashima Y; Sato T; Hirose K; Kanegasaki S; Matsushima K
J Immunol; 2009 Nov; 183(10):6387-94. PubMed ID: 19841162
[TBL] [Abstract][Full Text] [Related]
12. Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?
Coll B; Alonso-Villaverde C; Joven J
Clin Chim Acta; 2007 Aug; 383(1-2):21-9. PubMed ID: 17521622
[TBL] [Abstract][Full Text] [Related]
13. Isolation and structures of novel fungal metabolites as chemokine receptor (CCR2) antagonists.
Herath KB; Jayasuriya H; Ondeyka JG; Polishook JD; Bills GF; Dombrowski AW; Cabello A; Vicario PP; Zweerink H; Guan Z; Singh SB
J Antibiot (Tokyo); 2005 Nov; 58(11):686-94. PubMed ID: 16466022
[TBL] [Abstract][Full Text] [Related]
14. Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2.
Zweemer AJ; Nederpelt I; Vrieling H; Hafith S; Doornbos ML; de Vries H; Abt J; Gross R; Stamos D; Saunders J; Smit MJ; Ijzerman AP; Heitman LH
Mol Pharmacol; 2013 Oct; 84(4):551-61. PubMed ID: 23877010
[TBL] [Abstract][Full Text] [Related]
15. CCL2 binding is CCR2 independent in primary adult human astrocytes.
Fouillet A; Mawson J; Suliman O; Sharrack B; Romero IA; Woodroofe MN
Brain Res; 2012 Feb; 1437():115-26. PubMed ID: 22226505
[TBL] [Abstract][Full Text] [Related]
16. Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis.
Terashima Y; Onai N; Murai M; Enomoto M; Poonpiriya V; Hamada T; Motomura K; Suwa M; Ezaki T; Haga T; Kanegasaki S; Matsushima K
Nat Immunol; 2005 Aug; 6(8):827-35. PubMed ID: 15995708
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2.
Izhak L; Wildbaum G; Zohar Y; Anunu R; Klapper L; Elkeles A; Seagal J; Yefenof E; Ayalon-Soffer M; Karin N
J Immunol; 2009 Jul; 183(1):732-9. PubMed ID: 19535619
[TBL] [Abstract][Full Text] [Related]
18. Identification of CCR2-binding features in Cytl1 by a CCL2-like chemokine model.
Tomczak A; Pisabarro MT
Proteins; 2011 Apr; 79(4):1277-92. PubMed ID: 21322034
[TBL] [Abstract][Full Text] [Related]
19. A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart.
Satoh M; Akatsu T; Ishkawa Y; Minami Y; Nakamura M
J Card Fail; 2007 Mar; 13(2):114-9. PubMed ID: 17395051
[TBL] [Abstract][Full Text] [Related]
20. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
